Successful treatment of facial localized discoid lupus erythematosus with intralesional betamethasone: A report of three cases.
Dermatol Ther
; 33(3): e13389, 2020 05.
Article
em En
| MEDLINE
| ID: mdl-32268443
ABSTRACT
Discoid lupus erythematosus (DLE) is a chronic autoimmune skin disease that usually causes disfiguring scarring, dyspigmentation, and atrophy. Despite a range of available topical and systemic therapies, the treatment of DLE remains a therapeutic challenge, especially in some refractory cases. Here, we reported three male patients with long-term chronic lesions of unilateral facial localized DLE, who failed to have their disease controlled with many previous topical/systemic treatments, showed rapid and well response to intralesional injections of betamethasone (2 mg/mL, 0.2 mL/site) monotherapy once every 2 weeks for two, two, and four times of treatment, respectively. Intralesional betamethasone may provide a safe and effective alternative in the management of refractory localized DLE skin lesions.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Betametasona
/
Lúpus Eritematoso Discoide
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
Dermatol Ther
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
China